Epileptic encephalopathy is a group of severe brain disorders in which seizures and abnormal electrical activity in the brain directly worsen cognitive function, behavior, and development beyond what the underlying cause alone would explain. These conditions primarily affect infants and young children, and the core problem is that the brain’s constant misfiring disrupts normal development during a critical window of growth. More than 100 genetic causes have been identified over the past two decades, and treatment focuses on controlling seizure activity as early as possible to limit ongoing damage.
How Seizure Activity Damages the Developing Brain
In most forms of epilepsy, seizures are a symptom of an underlying brain problem. In epileptic encephalopathy, the seizures themselves become part of the problem. Even between visible seizures, the brain produces frequent bursts of abnormal electrical discharges. These discharges interfere with the normal signaling that a developing brain relies on to build language, memory, motor skills, and social abilities. The result is that a child’s development slows, stalls, or actively regresses in ways that go well beyond what the original brain abnormality would cause on its own.
This distinction matters for treatment. Because the electrical activity is doing the damage, aggressively controlling seizures and abnormal discharges can, in some cases, slow or partially reverse cognitive decline. The earlier this happens, the better the chances of preserving developmental potential.
Developmental vs. Epileptic Encephalopathy
Doctors now recognize that these conditions exist on a spectrum. In a purely developmental encephalopathy, a genetic mutation or structural brain problem impairs development regardless of whether seizures occur. Treating seizures in these cases won’t significantly improve cognition. In a purely epileptic encephalopathy, the seizure activity is the primary driver of developmental problems, and controlling it can make a real difference.
Many children fall somewhere in between, which is why the term “developmental and epileptic encephalopathy” (DEE) has become common. In practice, the clearest sign that epileptic encephalopathy is at play is when a child shows a defined timeline of developmental regression that coincides with new, significant abnormal activity on an EEG (the test that measures brain electrical patterns). This timeline helps doctors decide how aggressively to pursue seizure control.
Common Causes
Most cases are genetic. The most frequently identified genes include SCN1A, STXBP1, SCN2A, and KCNQ2. These genes typically encode proteins that control how electrical signals pass through brain cells, so mutations in them create the kind of widespread electrical instability that drives these conditions. Most of these mutations arise spontaneously (de novo), meaning neither parent carries the mutation. Brain MRI scans are often completely normal in children with genetic forms, which can be frustrating for families looking for a visible explanation.
Less commonly, structural brain malformations, metabolic disorders, or brain injuries from infection or oxygen deprivation before or during birth can trigger epileptic encephalopathy. Metabolic causes are especially important to identify because some are treatable. Doctors typically run a first round of blood and urine tests that can catch most reversible metabolic conditions. These screening tests are relatively affordable and non-invasive. If results are inconclusive, more targeted testing follows based on the child’s specific symptoms.
Major Syndromes
Infantile Epileptic Spasms Syndrome
Previously called West syndrome, this is one of the most recognized forms. It typically appears between 3 and 12 months of age. The hallmark is epileptic spasms: brief, sudden clusters of jerking movements, often occurring as a child wakes up. The EEG shows a chaotic pattern called hypsarrhythmia, with disorganized, high-voltage waves across the entire brain. Children with this syndrome experience developmental plateauing or regression, sometimes losing skills they had already gained like babbling or reaching for objects.
Three first-line treatments exist: oral corticosteroids, adrenocorticotropic hormone (ACTH, a hormone injection that stimulates the body’s own steroid production), and vigabatrin (a medication that increases levels of a calming brain chemical called GABA). The choice depends on the suspected cause and the child’s response. Speed matters here. Starting treatment within days of diagnosis improves the chances of stopping the spasms and limiting developmental harm.
Lennox-Gastaut Syndrome
This syndrome usually begins between ages 1 and 7, and some children transition into it after infantile spasms. It involves multiple seizure types. Tonic seizures (sudden stiffening of the body) are required for diagnosis, along with at least one other type, such as atypical absence seizures (prolonged staring episodes that start and end gradually) or atonic seizures (sudden loss of muscle tone causing “drop attacks”). The EEG shows a distinctive slow spike-and-wave pattern at 2.5 Hz or less, most prominent over the frontal regions of the brain.
Lennox-Gastaut syndrome is notoriously difficult to treat. Seizures are often resistant to medication, and the combination of frequent seizures and ongoing abnormal brain activity contributes to progressive intellectual disability and behavioral challenges.
The Ketogenic Diet as Treatment
When medications fail to control seizures, the ketogenic diet is one of the most established non-drug options. This high-fat, very low-carbohydrate diet forces the brain to use fat-derived molecules for energy instead of glucose, which appears to stabilize electrical activity through mechanisms that aren’t fully understood.
In a study of children with genetically confirmed developmental and epileptic encephalopathy who began having seizures within the first six months of life, 81.3% experienced at least a 50% reduction in seizure frequency on the ketogenic diet, and 37.5% became completely seizure-free for six months or more. Results varied by genetic cause. Children with STXBP1 mutations responded particularly well, with four out of five achieving complete seizure freedom. Those with SCN1A mutations all saw meaningful improvement, though complete freedom was less common. Children with certain other mutations, like KCNT1, had lower response rates.
The diet requires close medical supervision because it changes the body’s metabolism significantly and can cause side effects like kidney stones, high cholesterol, and growth slowing. Families typically work with a specialized dietitian to maintain the strict ratios needed for the diet to work.
Long-Term Outlook
Outcomes vary widely depending on the specific syndrome, the underlying cause, and how quickly effective treatment begins. Research tracking children with infantile epileptic spasms syndrome provides a useful window into what families can expect. Three years after spasms began, about 65% of children had achieved favorable seizure control, meaning they were either seizure-free or had only mild focal seizures rather than spasms. By seven years, that number dropped to about 55%, reflecting the tendency for new seizure types to emerge over time.
Developmental outcomes are more sobering. At three years, roughly 61% of children had poor developmental outcomes, defined as an IQ or developmental quotient below 35. By seven years, that figure rose to about 72%. These numbers underscore why early, aggressive treatment is so important: the window for protecting developing brain circuits is narrow, and delays in diagnosis or treatment can have lasting consequences.
Children who respond well to initial treatment and achieve early seizure freedom consistently have better cognitive outcomes. Genetic testing has become increasingly important not just for diagnosis but for guiding treatment choices, since certain genetic causes respond better to specific therapies. A child with a STXBP1 mutation, for example, may be fast-tracked to the ketogenic diet based on the strong response rates seen in that group.